19192-Lung Cancer-NSCLC-564

Lung Cancer

A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)

  • Details

ClinicalTrials.gov ID: NCT04294810
Diagnosis Type: NSCLC
USOR Number:

  • Address

8820 Huron St
Thornton, CO 80260
P: (303) 386-7622

Search by practice name, trial titles, indicators and specific disease types.

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.